

# Quantoom Biosciences Expands U.S. Market Reach with Key Appointments

Nivelles – May 31 2023

Quantoom Biosciences S.A. (“Quantoom”), a Univercells company, is establishing a team in the United States. The company has appointed Oladimeji Fashola as Chief Technology Officer, and a Business Development team of three. These crucial additions mark an exciting phase of growth for the company and underline its commitment to expanding its presence in the U.S. market.

The fast development of effective COVID-19 vaccines has provided proof of concept to a promising platform modality that has the great potential to deliver many new, more effective, or more personalized medicines for patients in need. However, innovation in process development and manufacturing will be required to avoid bottlenecks in the swift and cost-effective progress of the growing and increasingly diverse candidate pipelines toward commercialization around the world.

*"We are delighted to welcome Oladimeji and the new Business Development team to the Quantoom family,"* said José Castillo, CEO of Quantoom Biosciences. *"Their expertise, industry insight, and leadership will be instrumental in demonstrating the value of our innovation and in creating partnerships to advance our goal to accelerate the availability of new mRNA therapeutics and vaccines thanks to better, faster and more cost-effective process development and manufacturing."*

Oladimeji Fashola brings extensive operations and strategic product lifecycle management experience in cell and gene therapy, RNA and recombinant protein manufacturing. He has been working in the biopharma industry for the past 15 years in roles, specializing process development, technology transfer, process qualification used to support clinical and commercialization and strategic sourcing.

*"I am thrilled to join such a dynamic and forward-thinking company. Quantoom's innovation in mRNA production aligns perfectly with my passion for technological progress for the benefit of patients. I am eager to contribute my expertise and collaborate with my like-minded new colleagues to accelerate the development and use of Nfinity™, Quantoom's mRNA production platform,"* said Oladimeji, Chief Technology Officer of Quantoom Biosciences.

Quantoom Biosciences Nfinity™ platform advances and accelerates cost-effective mRNA process development thanks to process intensification, integration and automation. It offers enhanced productivity and quality alongside seamless scaling, with reduced operational costs and capital investment needs.

###

## About Quantoom Biosciences

Quantoom Biosciences is reinventing mRNA production by developing an RNA Platform (Nfinity™) that encompasses DNA (Nplify™) and RNA (Ntensify™) manufacturing and formulation (Ncapsulate™), along with critical reagent supply, from small to larger scale, ideally for pre-clinical and clinical study or trial projects. We are a team of scientists, engineers and clinicians committed to solving some of the biggest DNA and RNA production challenges facing vaccines and therapeutics, by delivering greater access and autonomy to mRNA technology. Our facilities are strategically located in Belgium and France, in the heart of Europe, benefiting from an exceptional biotech ecosystem. Quantoom Biosciences is part of Univercells, a global life sciences Group with the mission of making biologics accessible to all".

[www.quantoom.com](http://www.quantoom.com)

## Contact details

### Quantoom Biosciences S.A.

José Castillo  
Chief Executive Officer  
[press@quantoom.com](mailto:press@quantoom.com)

### BE & FR Media Relations

Cécile Hisette  
[Info@cecili-z.be](mailto:Info@cecili-z.be)  
+32.473.36.14.11

## Disclosure Statement

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.